89 [28] Blaise D, Tabrizi R, Boher JM, et al. Randomized study of 2 reduced-intensity conditioning strategies for human leukocyte antigen-matched, related allogeneic peripheral blood stem cell transplantation: prospec- tive clinical and socioeconomic evaluation. Cancer. 2013;119:602–11 [29] Bornhäuser M, Kienast J, Trenschel R, et al. Reduced- intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first com- plete remission: a prospective, open-label randomised phase 3 trial. Lancet Oncol. 2012;13:1035–44 [30] Scott BL, Pasquini MC, Logan BR, et al. Myeloablative versus reduced-intensity hematopoietic cell transplan- tation for acute myeloid leukemia and myelodysplas- tic syndromes. J Clin Oncol. 2017;35:1154–61 [31] Kharfan-Dabaja MA, Labopin M, Polge E, et al. Association of second allogeneic hematopoietic cell transplant vs donor lymphocyte infusion with over- all survival in patients with acute myeloid leukemia relapse. JAMA Oncol. 2018. https://doi. org/10.1001/ jamaoncol.2018.2091 [32] Lee CJ, Savani BN, Mohty M, et al. Haploidentical hema- topoietic cell transplantation for adult acute myeloid leukemia: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2017;102:1810–22 [33] Baron F, Mohty M, Blaise D, et al. Anti-thymocyte glob- ulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell trans- plantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2017;102:224–34 [34] Pascal L, Mohty M, Ruggeri A, et al. Impact of rabbit ATG-containing myeloablative conditioning regi- mens on the outcome of patients undergoing unrelated single-unit cord blood transplantation for hema- tological malignancies. Bone Marrow Transplant. 2015;50:45–50 [35] Ruggeri A, Sanz G, Bittencourt H, et al. Comparison of outcomes after single or double cord blood trans- plantation in adults with acute leukemia using dif- ferent types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT. Leukemia. 2014;28:779–86 [36] Lee CJ, Savani BN, Mohty M, et al. Haploidentical hema- topoietic cell transplantation for adult acute myeloid leukemia: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2017;102:1810–22 [37] Ruggeri A, Labopin M, Bacigalupo A, et al. Post- transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT. J Hematol Oncol. 2018;11:40 [38] Baron F, Ruggeri A, Beohou E, et al. RIC versus MAC UCBT in adults with AML: a report from Eurocord, the ALWP and the CTIWP of the EBMT. Oncotarget. 2016;7:43027–38 [39] Savani BN, Labopin M, Kröger N, et al. Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity condi- tioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT. Haematologica. 2016;101:773–80 [40] Mills W, Chopra R, McMillan A, et al. BEAM chemo- therapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin’s lymphoma. J Clin Oncol. 1995;13:588–95 [41] Vose JM, Carter S, Burns LJ, et al. Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial. J Clin Oncol. 2013;31:1662–8 [42] Gorin NC, Giebel S, Labopin M, et al. Autologous stem cell transplantation for adult acute leukemia in 2015: time to rethink? Present status and future prospects. Bone Marrow Transplant. 2015;50:1495–502 [43] Gorin NC, Labopin M, Czerw T, et al. Autologous stem cell transplantation for adult acute myelocytic leuke- mia in first remission-Better outcomes after busulfan and melphalan compared with busulfan and cyclo- phosphamide: a retrospective study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Cancer. 2017;123:824–31 [44] Cohn SL, Pearson ADJ, London WB, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG task force report. J Clin Oncol. 2009;27:289–97 [45] Moroz V, Machin D, Faldum A, et al. Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblas- toma: a report from the International Neuroblastoma Risk Group Project. Eur J Cancer. 2011;47:561–71 [46] Ladenstein R, Pötschger U, Pearson ADJ, et al. Busulfan and melphalan versus carboplatin, etoposide, and mel- phalan as high-dose chemotherapy for high-risk neu-roblastoma (HR-NBL1/ SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. Lancet Oncol. 2017;18:500–14 [47] Park JR, Kreissman SG, London WB, et al. A phase III randomized clinical trial (RCT) of tandem myeloab- lative autologous stem cell transplant (ASCT) using peripheral blood stem cell (PBSC) as consolida- tion therapy for high-risk neuroblastoma (HR-NB): a Children’s Oncology Group (COG) study. J Clin Oncol. 2016;34(18_Suppl):LBA3.https://doi.org/10.1200/JCO.2016.34.18_ suppl.LBA3 [48] Luksch R, Tienghi A, Hall KS, et al. Primary meta- static Ewing’s family tumors: results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV Study including myeloablative che- motherapy and total-lung irradiation. Ann Oncol. 2012;23:2970–6. [48] Tenneti P, Zahid U, Sagar F, et al. Role of high-dose chemotherapy and autologous stem cell transplanta- tion for relapsed Ewing’s sarcoma: a case report with focused review of literature. Cureus. 2018;10:e2581. [49] Whelan J, Le Deley MC, Dirksen U, Euro-E.W.I.N.G.99 and EWING-2008 Investigators, et al. High-dose chemotherapy and blood autologous stem-cell res- cue compared with standard chemotherapy in localized high-risk ewing sarcoma: results of Euro- E.W.I.N.G.99 and Ewing-2008. J Clin Oncol. 2018 [50] Admiraal R, van der Paardt M, Kobes J, et al. High-dose chemotherapy for children and young adults with stage IV rhabdomyosarcoma. CochraneDatabaseSyst Rev. 2010;12:CD006669 [51] Cohen BH, Geyer JR, Miller DC, et al. Pilot study of intensive chemotherapy with peripheral hematopoietic cell support for children less than 3 years of age with malignant brain tumors, the CCG-99703 phase I/II study. A report from the Children’s Oncology Group. Pediatr Neurol. 2015;53:31–46 [52] Marec-Berard P, Segura-Ferlay C, Tabone MD, et al. High dose thiotepa in patients with relapsed or refrac- tory osteosarcomas: experience of the SFCE Group. Sarcoma. 2014;2014:475067 [53] Fagioli F, Aglietta M, Tienghi A, et al. High-dose che- motherapy in the treatment of relapsed osteosarcoma: an Italian Sarcoma Group Study. J Clin Oncol. 2002;50:2150–6 1. Aspetti Generali
RkJQdWJsaXNoZXIy ODUzNzk5